Drug Profile
Research programme: diabetes therapeutics - MC2 Therapeutics
Latest Information Update: 27 Mar 2023
Price :
$50
*
At a glance
- Originator MC2 Biotek
- Developer MC2 Therapeutics
- Class Antihyperglycaemics; Small molecules
- Mechanism of Action Proto-oncogene protein c-bcl-2 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 27 Mar 2023 Discontinued - Preclinical for Type 2 diabetes mellitus in Denmark (PO)
- 28 Sep 2018 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in Denmark (PO)
- 23 Jan 2015 Research programme: diabetes therapeutics - mc2 biotek is available for licensing as of 23 Jan 2015. http://www.mc2biotek.com